Marleen van den Horst

T: +31 70 376 06 21
View Marleen van den Horst on LinkedIn

Head of the IP & Technology Practice Group  Marleen van den Horst (J.D.), has more than 20 years experience in conducting and coordinating complex, multi-jurisdictional patent proceedings in all fields of technology, including mechanical engineering, electronics, chemistry and life sciences.  Most of her clients are major players in the life sciences and high tech industry.

Marleen has frequently acted as lead counsel in patent/SPC and regulatory proceedings regarding molecules like (es)omeprazole, alendronate, (es)citalopram, glatiramer acetate, trastuzumab, rivastigmine, zoledronate, imatinib and, recently on  rituximab, tadalafil, ezetimibe+simvastatin and CRISPR-Cas9 technology. Apart from medical devices and medicinal products for human use, she has conducted litigation on e.g. veterinary vaccines and antimicrobial animal feed additives.

In the field of high tech/telecoms Marleen advises on European litigation strategy for enforcing mainly SEP patents and on FRAND-related issues. With her team she has is frequently asked to prepare the Dutch chapter of pan-European litigation in close cooperation with law firms in other countries.

Marleen is also involved in a number major mechanical patent cases concerning e.g.  floor panels connection systems and equipment for the production of biaxially oriented tubing (PVC-O) .

Apart from contentious work, she assists clients in negotiating and drafting licences, technology transfer and supply & distribution agreements and advises on managing IP assets

Marleen provides pro bono advice to the Dutch Neokidney Foundation regarding all patent and contractual issues that come up in the development of a portable artificial kidney.

Marleen is a frequent speaker on SPC, patent and regulatory topics at international conferences and national events and seminars.

Selected directory listings

Marleen Van Den Horst heads the practice at BarentsKrans which has ‘respected lawyers with a broad network’ and who ‘go into depth in understanding technology and provide a strategy‘. Van den Horst has decades of experience in relation to litigation over blockbuster drugs and regulatory proceedings. She is again recognised as ‘Leading Individual’ in Healthcare & Life sciences.- Legal 500, 2019

According to sources, Marleen van den Horst is ”a very good lawyer with excellent judicial skills.”Chambers Global 2019

Extremely personable’ regulatory and patents expert Marleen van den Horst, who has ‘a depth of experience few can rival‘, is now also named ‘Leading Individual’ in Healthcare and Life sciences.  – Legal 500, 2018

Clients praise her “outstanding knowledge, good commercial awareness and customer focus.” Chambers Global & Europe, 2018

Client Choice award received in the category ‘Healthcare & Life Sciences’ – Client Choice, 2018

Professional activities

Member of the Board of the NeoKidney Foundation
Member of various professional associations, including EPLAW, AIPPI, LES, HollandBio, VF&R

News and publications

Telecoms update | Provisions judge denies Fractus a preliminary injunction against Xiaomi et al.

On 10 December 2019, the Provisions Judge of the District Court of The Hague denied a cross-border preliminary injunction claimed by FRACTUS S.A. (‘Fractus’) against Xiaomi Technology Netherlands B.V. (‘Xiaomi’) and several Dutch smartphone vendors for the alleged infringement of Fractus’ patent EP 1 592 083 (‘EP ‘083’). According to Fractus the antennas of various
Read more ›

Pharma update: pemetrexed tromethamine does not infringe pemetrexed disodium patent

In its judgment of 19 June 2019, the District Court of The Hague ruled that Fresenius Kabi’s pemetrexed tromethamine falls outside the scope of protection of Eli Lilly’s patent for pemetrexed disodium. This final relief decision deviates from earlier decisions in interim relief proceedings and decisions by several foreign courts. Eli Lilly (“Lilly”) markets the
Read more ›
More from this specialist